FAK Activators for Mucosal Healing in GI Disorders

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

Current treatments for gastrointestinal mucosal injuries, such as those in Crohn's disease and peptic ulcers, primarily focus on reducing inflammation rather than promoting healing, leading to inadequate mucosal recovery and potential surgical complications.

Innovation Solution

Pharmacological activation of focal adhesion kinase (FAK) using small molecules to enhance phosphorylation and promote mucosal healing in gastrointestinal conditions, including Crohn's disease, ulcerative colitis, and peptic ulcers, through compounds that mimic the tertiary structure of FAK subdomains.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Object-affected harmful factors

If current immunosuppressive and anti-acid agents are used to reduce injury, then inflammation is reduced, but mucosal healing is inadequate

Engineering Contradiction:

Improveinflammation reductionVSAvoidmucosal healing adequacy

Core Design Contradiction:

Object-affected harmful factorsVSReliability

Solution Approach 1:

Instead of continuing to focus on reducing injury through immunosuppression, the invention inverts the approach by directly promoting mucosal healing through FAK activation. This shifts the therapeutic strategy from damage control to active regeneration, addressing the inadequacy of current healing outcomes.

Inventive Principle:

Principle #13The other way round (Inversion)

Solution Approach 2:

The invention changes the therapeutic parameter from immunosuppression to FAK pathway activation. By using small molecule compounds that specifically activate FAK phosphorylation, the treatment transitions from reducing inflammation to actively promoting epithelial migration and mucosal repair, thereby improving healing adequacy.

Inventive Principle:

Principle #35Parameter changes

2Object-affected harmful factors

If aggressive immunosuppression is administered, then inflammation is controlled, but surgical complications increase

Engineering Contradiction:

Improveinflammation controlVSAvoidsurgical complications

Core Design Contradiction:

Object-affected harmful factorsVSObject-generated harmful factors

Solution Approach 1:

The invention introduces FAK activation as an intermediary mechanism that bridges inflammation control and mucosal healing. By activating FAK, the treatment promotes epithelial sheet migration and mucosal repair, creating a protective barrier that reduces the need for surgery and associated complications.

Inventive Principle:

Principle #24Intermediary (Mediator)

Solution Approach 2:

The invention performs preliminary action by accelerating mucosal healing before surgical intervention becomes necessary. By promoting rapid epithelial repair through FAK activation, the treatment prevents the progression to surgical complications, addressing the problem proactively rather than reactively.

Inventive Principle:

Principle #10Preliminary action

3Adaptability or versatility

If repeated resections are performed, then disease flares are managed, but short gut syndrome develops

Engineering Contradiction:

Improvedisease flare managementVSAvoidsmall intestine length

Core Design Contradiction:

Adaptability or versatilityVSLoss of substance

Solution Approach 1:

The invention enables self-service by activating the body's own healing mechanisms through FAK phosphorylation. The small molecule compounds stimulate endogenous epithelial migration and proliferation, allowing the mucosa to repair itself without requiring surgical resection, thereby preserving small intestine length.

Inventive Principle:

Principle #25Self-service

Solution Approach 2:

The invention applies preliminary anti-action by preventing the need for repeated resections through accelerated mucosal healing. By promoting rapid repair of mucosal injuries, the treatment counteracts the progression to short gut syndrome before it occurs.

Inventive Principle:

Principle #9Preliminary anti-action

Applied Scientific Principles

This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.

Function Achieved in This Case

The compounds accelerate mucosal ulcer healing and epithelial sheet migration, demonstrating potential for synergistic use with immunosuppressives to reduce surgical risks and enhance quality of life for patients with gastrointestinal disorders.

Implementation Method 1

pharmacological intervention to activate or enhance the phosphorylation of FAK, thereby accelerating mucosal healing

Methodology Applied

Scientific EffectPhosphorylation:

Data Source

PatentUS20240408105A1Use of small molecule FAK activators to promote mucosal healing

Publication Date: 2024.12.12 UNIVERSITY OF NORTH DAKOTA

AI summary

Methods to activate or enhance phosphorylation of focal adhesion kinase (FAK) are provided herein. Methods to treat epithelial disorders in mammals. namely diseases of the gut. comprising the administration of one or more small molecules having FAK activation properties are also provided.